Frank Qian

3 weeks ago | pharmacytimes.com | Frank Qian |Alana Hippensteele

CommentaryVideoJune 2, 2025Author(s):,Frank Qian, MD, MPH, discusses the integration of omega-3 fatty acid therapy alongside statins and PCSK9 inhibitors in cardiovascular risk management, highlighting the distinct mechanisms of benefit and lack of significant drug interactions. As the landscape of cardiovascular disease management continues to evolve, understanding the diverse mechanisms and therapeutic roles of omega-3 fatty acids is essential for optimizing patient care.

3 weeks ago | pharmacytimes.com | Frank Qian |Alana Hippensteele

CommentaryVideoJune 1, 2025Author(s):,Frank Qian, MD, MPH, discusses clinical considerations for omega-3 fatty acid therapy, such as the patient populations who may benefit most and important safety concerns. As interest in omega-3 fatty acids continues to grow, so do questions about their clinical applications, safety, and efficacy.

4 weeks ago | pharmacytimes.com | Frank Qian |Alana Hippensteele

CommentaryVideoMay 31, 2025Author(s):,Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of recent trial findings. Omega-3 fatty acids have long been recognized for their role in lipid management, but their clinical applications, particularly for cardiovascular risk reduction, continue to evolve.